My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.08 -0.10 (-0.66%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 09, 2023

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

April 17, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China ↗

January 23, 2023

Via Benzinga

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

April 11, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Intended Retirement of Independent Non-executive Director

April 11, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗

April 08, 2023

Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...

Via Talk Markets

Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 06, 2023

Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719.

Via Benzinga

Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday ↗

April 06, 2023

U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 04, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.

Via Benzinga

Why Is HUTCHMED Stock Trading Higher Today? ↗

April 04, 2023

HUTCHMED (China) Limited (NASDAQ: HCM) shares are trading higher on Tuesday after the company initiated enrollment registration for its ongoing Phase 2 trial of HMPL-453 for intrahepatic...

Via Benzinga

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

April 04, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

March 30, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

March 14, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

March 12, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 08, 2023

Gainers Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 08, 2023

Via Benzinga

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

February 28, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China

February 27, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 10, 2023

Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...

Via Benzinga

Lyft, BARK And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

February 10, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

HUTCHMED to Announce 2022 Final Results

January 31, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday ↗

January 30, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

January 23, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

January 18, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Constellation Brands, Walgreens, RPM International And Some Other Big Stocks Moving Lower On Thursday ↗

January 05, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

January 03, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

December 19, 2022

From HUTCHMED (China) Limited

Via GlobeNewswire

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

December 16, 2022

From Prenetics Limited

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.